PSM Interchange 2014 Panel 3, Libby Baney, The Impact of Fake Online Pharmacies on Patient Safety

•Download as PPTX, PDF•

0 likes•1,457 views

Libby Baney, Executive Director for the Alliance for Safe Online Pharmacies talks about the current state of rogue online pharmacies and efforts to curb them.

Health & Medicine

The Impact of Fake
Online Pharmacies on
Patient Safety
Libby Baney, J.D., Executive Director, ASOP
Partnership for Safe Medicines Interchange
September 18, 2014

What We Know: Data
• 40,000-50,000 active online drug sellers
operating globally (LegitScript)
• 97% of online drug seller sites are operating
in violation of applicable laws (NABP)
• 50% of the prescription medicines sold online
by websites that hide their physical address
are counterfeit (WHO)

What We Know: Data
Illegal online drug sellers are the most frequent
conduit of counterfeit drugs (NABP)
23% of adult Internet consumers surveyed
have bought prescription medicine online (US
FDA)
Illegal online drug sellers can make $1 million
and $2.5 million in sales each month (MIT)

Risks to Patient Safety:
Illegal online drug sellers:
1. Sell prescription-only medicines
without a valid prescription.
2. Sell unapproved, adulterated,
misbranded or counterfeit drugs
3. Do not have the required
pharmacy license in
the jurisdictions it ships drugs to.

Headlines from August and September 2014

Examples of Patients Harmed
Lorna Lambden
No medical exam; bought unapproved sleeping pills
Died from drug interaction
Marcia Bergeron
Fake drugs bought from illicit online pharmacy
Heavy metal poisoning (lead, titanium, arsenic)
Steven Kovacs
Bought prescription drugs online without a prescription
Overdosed and died / no medical supervision

Five Signs We Are Making An Impact
1. Internet commerce companies agree to take voluntary
action against illegal online drug sellers
• Visa issues Internet Pharmacy Guide for Acquirers
• CSIP issues Principles of Participation
• Realtime Register B.V. (Netherlands) changes practices
Top 10 Registrars Harboring Rogue Pharmacies
1. TodayNIC (China)
2. BizCN (China)
3. Gransy (Czech Republic)
4. Joker.com (Germany)
5. Momentous Group/Rebel.com (Canada)
6. Paknic (Pakistan)
7. WebNIC.cc (Malaysia)
8. Dattatec (Argentina)
9. IPMirror (Singapore)
10. Domain.com (US)

Five Signs We Are Making An Impact
2. Transatlantic IPR Working Group prioritizes Internet
pharmacies
3. APEC creates an Internet Sales Working Group
• ASOP helps lead engagement with 21 economies

Five Signs We Are Making an Impact
4. DotPharmacy launches (Fall 2014)
5. ASOP raises public awareness
• ASOP issuing a CME/CPE program with the Federation of State
Medical Boards
• ASOP and CSIP run a search advertising campaign:
5.5+ million hits to date
• ASOP speaks at 20+ events annually

ASOP is a nonprofit organization with the mission to protect patient safety globally
Federation of State Medical
Boards
National Health Council
National Association of
Boards of Pharmacy
PhRMA
Partnership for Safe
Medicines
Rx-360
APhA
LegitScript
Amgen
Merck
Boehringer Ingelheim
Men’s Health Network
Consumer Healthcare
Information Corp
NACDS
Eli Lilly & Company
NeedyMeds
ASOP Observers
MEMBERS
EAASM
NOVA ScriptCentral
GPhA
Takeda
International Pharmaceutical
Federation
Italian Medicines Agency
Partnership for Drug-Free
Kids
U.S. Pharmacopeia
Convention

I have been working on the topic of anti-counterfeiting for a number of years and find myself increasingly engrossed and thoroughly surprised as our understanding of this topic grows. The imagination and the brutality with which the criminal industry produces, distributes and sells imitation goods is unmatched. The consequences of such dire acts are not only killing children but also affecting the lives of many and fighting such forgery has become a personal battle for me.

Counterfeits Kill

cmebahamas

Counterfeit drugs pose a major global problem and public health risk. According to the World Health Organization, over half of counterfeit drug cases found no active ingredients, while others contained incorrect or dangerous ingredients. Developing countries are especially impacted, with up to 60% of reported counterfeit drugs. Counterfeiting undermines healthcare systems and can have deadly consequences. The document warns that weak drug regulation and an unsecured supply chain allow for counterfeits to proliferate. It advocates purchasing from authorized drug distributors only to help strengthen oversight of the pharmaceutical supply system.

Public Opinion On Prescription Drugs And Their Prices

KFF

- According to polls from 2015-2019, around 6 in 10 Americans currently take at least one prescription medication and 1 in 4 take 4 or more. While most say the cost of prescription drugs is unreasonable, around 3 in 4 currently taking medications say affording them is easy. However, those taking more medications report more cost problems. - Around 3 in 10 Americans have not taken their medication as prescribed at some point due to costs, such as not filling a prescription, cutting pills in half, or taking over-the-counter drugs instead. - Majorities of the public favor policies to lower drug costs like requiring list prices in ads, easier generics, and government negotiations. However, views on the best approach vary by

Prescription Medicines Costs in Context May 2020

PhRMA

This document discusses prescription drug costs and spending in the United States. It notes that while 56 new medicines were approved by the FDA in 2019, out-of-pocket costs for patients continue to rise. While overall spending on prescription drugs grew by just 2.5% in 2018, nearly half of brand drug spending goes to entities other than the manufacturers. The document also compares US drug costs and availability to other countries.

Detection of Counterfeit Drugs and Other Products

Nancy Sperling

Evaluate Minnesota Pharma Market Landscape 2017

Evaluate Ltd

This document summarizes pharmaceutical research and development in Minnesota. It notes that 19 products are currently in active clinical development with the FDA. The top five therapy areas for ongoing clinical trials by Minnesota entities are oncology, central nervous system disorders, anti-infectives, cardiovascular disorders, and endocrine disorders. Minnesota's current FDA approval pipeline includes pre-clinical and phase 1, 2, and 3 clinical trials. The top three companies conducting these trials are the University of Minnesota, Mayo Clinic, and 3M.

Counterfeit Drugs in America: 2017 Overview

The Partnership For Safe Medicines

The antibody service and more efficient processes

bostonmol

This document discusses StreetRx.com, a crowdsourced platform that collects anonymous street price data on diverted pharmaceutical drugs. It has received over 42,000 referrals to health organizations since 2010. The document examines whether abuse-deterrent drug formulations (ADFs) can be distinguished from original formulations based on their street prices. Analysis of over 49,000 price entries found that most ADFs had significantly higher street prices than their non-ADF counterparts, indicating the black market can potentially discriminate between different abuse-deterrent technologies and formulations.

StreetRx Price Comparison

epidemico

StreetRx collects crowdsourced data on street prices of diverted pharmaceuticals to monitor abuse trends. The document analyzes this data, finding that bulk purchases (10+ units) receive significant discounts compared to individual "retail" purchases for many drug classes, including benzodiazepines, muscle relaxers, erectile dysfunction drugs, and opioids. For example, bulk alprazolam purchases receive a 34% discount on average. This data helps identify which drugs face greater diversion risks due to larger bulk discounts.

Crowdsourcing as a way to evaluate drug abuse in the community

epidemico

Can the black market predict which abuse-deterrent formulations are most successful? Drug companies are trying to make pills harder to crush, in order to deter injection and snorting. The FDA held a public meeting last October where industry experts revealed new secrets on how the products are made, and are putting together a guidance on how to evaluate whether new drugs are really abuse deterrent, and whether pharma companies get to promote that way. Nabarun Dasgupta of Epidemico is presenting today at a new conference of FDA and industry on what black market street prices can reveal about ADFs.

Covid19 Tracker for week 14

Jean 'JP' Parker

Tracker 14 sample

Jean 'JP' Parker

This document is a weekly report from Vypr's COVID-19 Consumer Impact Tracker that measures how consumer behavior is changing in response to the coronavirus pandemic. It tracks 14 metrics related to lifestyle changes, shopping behavior, spending, and attitudes based on surveys of 500 UK consumers. The report shows changes between surveys conducted on March 19th and 25th, with increases seen in people working from home, limiting travel and social interactions, and spending more on groceries and personal care items. Overall it aims to track the evolving impact of the crisis on consumer behavior over time.

Uk%20 stats

Hola Social Media

The document summarizes statistics about UK consumers' mobile commerce behaviors: 24% of UK consumers have used smartphones to access websites while shopping; 48% accessed retail websites and 50% accessed social media sites on their phones while shopping; 40% of smartphone shoppers ultimately made a purchase in-store, online or via mobile. 55% of UK consumers have seen a QR code while shopping and 33% of those who saw one scanned it. 48% of UK smartphone owners use their phones to research products before purchase.

Cannabis Science & Policy Summit - Day 1 - Fortin

CannabisSummit

1) The document analyzes cannabis policy and markets in Colorado following legalization of recreational cannabis. 2) It finds evidence that the recreational market is cannibalizing the medical market, especially in tourist counties, but is also expanding overall demand. 3) A dual pricing scheme, with lower prices for medical patients and higher prices for recreational users, has successfully achieved price discrimination and appears optimal for balancing economic and social outcomes.

Where Food Comes From - Overview

Where Food Comes From, Inc.

This document discusses Where Food Comes From, Inc., a company that provides third-party verification and certification services for food producers. It has three main auditing divisions that verify various product attributes and certifications. The document outlines many of the standards, certifications, and attributes that the company can currently verify. It also discusses the importance of third-party verification and traceability in validating claims about food production practices and meeting consumer demand for transparency.

CBD Marketing Guide

gsetton

Your CBD business plan has to cover a lot of ground. Regulatory hurdles. Supply chain inconsistency. Marketing restrictions. And even if all those issues are addressed, you still have to create a credible brand in a crowded marketplace. Fortunately, GemmaCert is here to help. We’ve assembled this guide with valuable information for creating a great CBD business. Because our executive team has extensive experience in the dietary supplement industry — and because CBD is regulated like a dietary supplement in many jurisdictions — we can help CBD businesses navigate the market.

Cpha deck

The Partnership For Safe Medicines

This document discusses the Partnership for Safe Medicines, an organization advocating for safe medication access. It lists over 100 member organizations and provides information on counterfeit drugs including examples during the COVID-19 pandemic of fake vaccines, testing kits, and medicines being sold. Data is presented on rising drug overdose deaths in the US driven largely by fentanyl, and examples are given of recent seizures of counterfeit pills containing fentanyl in various states and countries that are fueling the opioid crisis.

Prescription Medicines Costs in Context October 2020

PhRMA

This document discusses the costs and affordability of prescription medicines in the United States. It notes that while spending on prescription medicines accounts for only 14% of total health care spending, patients face high and rising out-of-pocket costs for medicines. While most medicines sold in the US are generics, brand name medicines face significant price negotiations and rebates paid to insurers and pharmacy benefit managers that often do not lower costs for patients. The document outlines reforms to make medicines more affordable and accessible for patients.

Roadshow Europe Crazy4media - Javier Correro

mobilesquared Ltd

Mobile marketing is gaining popularity in Europe, with 40% of marketers currently using it and 28% planning to start campaigns in the next 12 months. Mobile app adoption among European mobile marketers is 38%, though only 7% of European consumers regularly download apps. Europeans are more likely to browse mobile websites than download apps, and the number of mobile web browsers has doubled in several European countries in the past year. SMS and MMS are popular mobile marketing tactics, used by 40% of mobile marketers.

Prescription Medicines Costs in Context April 2022

PhRMA

This document discusses the costs of prescription medicines in the United States. It notes that 60 new medicines were approved by the FDA in 2021 for cancer, hemophilia, and COVID treatments. While brand medicine prices declined slightly in 2020, overall medicine spending grew modestly due to rebates and discounts. The majority of medicine spending goes to entities other than the manufacturers, such as insurers, pharmacy benefit managers, and providers. The document argues for reforms that make insurance work better for patients, modernize Medicare drug coverage, protect safety net programs, and end misaligned incentives in the system.

Global Mobile Commerce Trends

MobiCommerce

Prescription Medicines Costs in Context March 2022

PhRMA

This document discusses trends in prescription drug costs and spending in the United States. It notes that 60 new medicines were approved by the FDA in 2021 for cancer, hemophilia, and COVID. While brand drug prices declined slightly in 2020, overall drug spending grew modestly. Most drug spending goes to health insurers, pharmacy benefit managers, and other entities rather than drug manufacturers. The majority of drugs dispensed are generics, which provide billions in savings each year. The document argues that while drug spending is projected to increase at a similar rate as overall healthcare costs, patients still face high out-of-pocket costs due to deductibles, coinsurance, and other cost-sharing policies by insurers.

Cannabis Science & Policy Summit - Day 1 - MacCoun

CannabisSummit

This document summarizes key points from Jon's talk on cannabis legalization. It notes that national legalization following an alcohol model is likely. Long-run cannabis consumption may double. Prices and quantity consumed matter more than the number of consumers. There are many policy levers but it is unclear if they are being used effectively to learn what works. National legalization is not guaranteed and effects in states like Colorado are still uncertain due to many complicating factors. The fundamental tradeoff is that legalization may reduce average harm per dose while increasing total doses consumed, with the net public health effect unknown.

Prescription Medicines - Costs in Context - October 2018

PhRMA

This document discusses the costs and context of prescription medicines. It notes that while prescription drug spending is a small percentage of total healthcare costs, certain patients face rising out-of-pocket costs. It also outlines the significant costs and risks of developing new medicines, with the average drug taking over 10 years and $2.6 billion to develop. The document proposes reforms to help lower costs for patients while supporting continued research and development of new treatments.

Prescription Medicines Costs in Context November 2019

PhRMA

This document discusses the costs and context of prescription medicines. It notes that while prescription drug spending is a small percentage of total healthcare spending, patients often face high out-of-pocket costs. It outlines the significant costs and risks of drug research and development. The document also describes the role of generics in reducing costs over time and how rebates and discounts do not always lower costs for patients.

NeedyMeds May 2017 webinar

The Partnership For Safe Medicines

Beyond Avastin: The ongoing dangers of counterfeit drugs to American patients

The Partnership For Safe Medicines

PSM Interchange 2014: Tim Mackey, After Avastin: What Have We Learned, What C...

The Partnership For Safe Medicines

What's hot

"Protecting Patients from Counterfeit Medicines," Congressional Briefing, Mar...

The Partnership For Safe Medicines

Crowdsourcing abuse deterrent formulation street price differentials

epidemico

StreetRx Price Comparison

epidemico

Crowdsourcing as a way to evaluate drug abuse in the community

epidemico

Covid19 Tracker for week 14

Jean 'JP' Parker

Tracker 14 sample

Jean 'JP' Parker

Uk%20 stats

Hola Social Media

Cannabis Science & Policy Summit - Day 1 - Fortin

CannabisSummit

Where Food Comes From - Overview

Where Food Comes From, Inc.

CBD Marketing Guide

gsetton

Cpha deck

The Partnership For Safe Medicines

Prescription Medicines Costs in Context October 2020

PhRMA

Roadshow Europe Crazy4media - Javier Correro

mobilesquared Ltd

Prescription Medicines Costs in Context April 2022

PhRMA

Global Mobile Commerce Trends

MobiCommerce

Prescription Medicines Costs in Context March 2022

PhRMA

Cannabis Science & Policy Summit - Day 1 - MacCoun

CannabisSummit

Prescription Medicines - Costs in Context - October 2018

PhRMA

Prescription Medicines Costs in Context November 2019

PhRMA

NeedyMeds May 2017 webinar

The Partnership For Safe Medicines

What's hot (20)

"Protecting Patients from Counterfeit Medicines," Congressional Briefing, Mar...

Crowdsourcing abuse deterrent formulation street price differentials

StreetRx Price Comparison

Crowdsourcing as a way to evaluate drug abuse in the community

Covid19 Tracker for week 14

Tracker 14 sample

Uk%20 stats

Cannabis Science & Policy Summit - Day 1 - Fortin

Where Food Comes From - Overview

CBD Marketing Guide

Cpha deck

Prescription Medicines Costs in Context October 2020

Roadshow Europe Crazy4media - Javier Correro

Prescription Medicines Costs in Context April 2022

Global Mobile Commerce Trends

Prescription Medicines Costs in Context March 2022

Cannabis Science & Policy Summit - Day 1 - MacCoun

Prescription Medicines - Costs in Context - October 2018

Prescription Medicines Costs in Context November 2019

NeedyMeds May 2017 webinar

Viewers also liked

Beyond Avastin: The ongoing dangers of counterfeit drugs to American patients

The Partnership For Safe Medicines

PSM Interchange 2014: Tim Mackey, After Avastin: What Have We Learned, What C...

The Partnership For Safe Medicines

PSM Interchange 2014: Madame Lihong Gu, Partnership for Safe Medicines, China

The Partnership For Safe Medicines

1. Partnership for Safe Medicines China (PSM China) was established in Beijing in November 2012 with participation from 12 associations to ensure a safe drug supply chain and educate patients and consumers on safe medication use. 2. PSM China's members include associations representing pharmaceutical manufacturers, distributors, hospitals, and licensed pharmacists. 3. In 2014, PSM China collaborated with Partnership for Safe Medicines India, launched a website, focused education efforts on medication for the elderly and chronic diseases, and organized over 180 volunteers to support educational programs.

PSM Interchange 2014: Scott LaGanga, Welcome to the 2014 Interchange

The Partnership For Safe Medicines

PSM Interchange 2014 Panel 3: Daniel Burke: The Impacts of Fake Online Pharma...

The Partnership For Safe Medicines

Dr. Marvin Shepherd: Grey Market Vendor Activities and Drug Shortages in Texa...

The Partnership For Safe Medicines

Marv Shepherd conducted research exploring whether hospital pharmacies could be a source of diverted drugs. A survey of Texas hospitals found that 25% reported being contacted by "grey market" vendors weekly or daily to purchase pharmaceuticals. Additionally, over 85% of hospitals reported being contacted by such vendors in the last month to sell drugs. While the size of this illicit market is unknown, the findings suggest some hospitals may be unlawfully diverting drugs. Further analysis found no significant associations between vendor contacts and hospital size, ownership, or location. The research indicates opportunistic vendors are actively trying to obtain drugs from some hospitals in Texas.

Be aware, take action: fight counterfeits, keep patients safer

The Partnership For Safe Medicines

The document summarizes initiatives to combat counterfeit medicines in various countries. It finds that healthcare professionals' roles are often unclear and they are not always at the forefront of counterfeiting issues. The WHPA campaign aims to strengthen advocacy for investing in healthcare professionals' education and capacity to detect, report, and prevent counterfeits. It establishes dialogue between stakeholders to share knowledge and resources and initiate cost-effective solutions. The WHPA Call to Action and toolkit provide strategies and resources to build comprehensive regional plans against counterfeiting through increasing professional capacity, regional cooperation, collaborative practice, and improved collaboration with authorities.

Luncheon Speaker: Bejon Misra, Partnership for Safe Medicines India

The Partnership For Safe Medicines

PSM India aims to: raise awareness of spurious drugs' harm; educate consumers and practitioners on drug quality and identifying suspected spurious drugs; and collaborate with the government and WHO. PSM held an international workshop on ensuring patient safety over commercial interests and regaining consumer confidence. A study found many small manufacturers lack Good Manufacturing Practices compliance and risk producing spurious drugs. It evaluated 348 essential drugs across India to understand the spurious drug problem's full extent and compliance with regulations. PSM plans to expand detection technologies statewide and work with regulators against law-violating manufacturers.

Panel 4 - Linda Marks Senior Counsel: Overview of New Developments in Interna...

The Partnership For Safe Medicines

The document summarizes a panel discussion on new developments in international cooperation to address challenges related to unapproved and counterfeit drugs. It describes problems like large quantities of prescription drugs coming from other countries and physicians ordering directly from unlicensed suppliers. Global challenges in investigations like tracing money and packages and obtaining evidence from other countries are also outlined. The panelists discuss international enforcement operations and USP programs that help strengthen quality assurance in developing countries.

Dr. Timothy Mackey: Clear and Present Danger: Availability of Dangerous, Unap...

The Partnership For Safe Medicines

Tim Mackey presented on the availability of dangerous, unapproved, and recalled drugs online. Some key points: - Research has found narrow therapeutic index drugs, drugs not approved for sale, and drugs under global recall are actively being marketed for sale without a prescription online. - The online drug ecosystem is complex, involving affiliate networks, business-to-business sellers, and emerging technologies like the dark web. - Moving forward, efforts should identify high-risk dangerous drugs, develop global lists of such drugs, map the entire illicit online pharmacy ecosystem, and prioritize enforcement against the worst offenders. The goal is to improve identification, surveillance and enforcement of clearly dangerous medicines available online without oversight.

Welcome remarks - Scott LaGanga Executive Director

The Partnership For Safe Medicines

The document summarizes the 2013 Interchange conference hosted by the Partnership for Safe Medicines (PSM). It lists the executive director of PSM and its many member organizations. It then describes PSM's efforts over the past year to educate over 300,000 patients, nurses, doctors and pharmacists, and nearly 1,000 at-risk clinics about counterfeit drugs through Facebook ads, printed materials, and trainings. PSM has also been working with international partners in countries like India, China, and Brazil. The conference agenda includes a new panel format and presentations on new research studies.

"Counterfeit Medicines: Threat to Public Health and Safety," Congressional Br...

The Partnership For Safe Medicines

This document discusses the threats posed by counterfeit medicines. It provides several examples of counterfeit medicines breaching the US supply chain and being distributed through "Canadian" websites and social media sites. The counterfeits have been found to contain no active ingredients, toxic ingredients, or incorrect doses of active ingredients. They are manufactured under unsafe conditions but can appear virtually indistinguishable from real medicines. The document emphasizes that counterfeit medicines pose a real threat to patient health and safety.

Panel 1: Patient Safety Moderated by Scott Williams

The Partnership For Safe Medicines

The document discusses how American patients have been impacted by unsafe and counterfeit medicines from 2010-2013. It describes several cases where medical professionals purchased non-FDA approved drugs and devices, exposing patients to risks. This includes expired, stolen, or improperly stored medicines. The document outlines issues with specific treatments like IUDs, Botox, osteoporosis drugs, HIV drugs, and diabetes treatments. Patients who received counterfeit versions faced potential health problems. While the full scope of the counterfeit drug problem in the US is unknown, the document argues it threatens patient safety when healthcare providers and patients cannot be certain the treatments they receive are real and effective.

PSM Interchange 2014 Panel 2: Linda Marks, Criminal Prosecutions: Patient Safety

The Partnership For Safe Medicines

PSM Interchange 2014 Panel 1: Tom Kubic, Global Trends Situation Report 2013

The Partnership For Safe Medicines

The UK (MHRA) approach to combating Falsified Medicines by Gerald Heddell, MHRA

The Partnership For Safe Medicines

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has developed a strategy to combat falsified medical products with the objective of reducing risks to patients and consumers. The strategy aims to enhance legal frameworks at the European Union and Council of Europe levels related to falsified medicines and strengthen safety features and controls for actors in the medical supply chain. It also addresses issues like internet sales of medicines and controls on active pharmaceutical ingredients.

Panel 2 Moderated by Dr. Bryan Liang Overview of Fake Online Pharmacy Issues

The Partnership For Safe Medicines

This document summarizes a panel discussion on issues related to fake online pharmacies. The panelists included pharmacists, law enforcement agents, and policy experts. They discussed how online pharmacies are difficult to regulate due to their ability to operate across state and international lines. While organizations like the FDA and NABP have programs to verify legitimate online pharmacies, illicit sites still proliferate using search engines, social media, and other online marketing techniques. Research presented found that consumers have difficulty identifying unsafe pharmacy websites and are willing to purchase medicines from illegal online pharmacies without prescriptions, including drugs that require close medical supervision.

PSM Interchange 2014 Panel 3: Todd Brown: Non-FDA Approved Foreign Drugs Are ...

The Partnership For Safe Medicines

Non-FDA approved foreign drugs are being provided to Massachusetts patients through online pharmacies, putting their health at risk. These drugs may contain toxic fillers, expired ingredients, or lack important safety information. Several health groups and trusts in Massachusetts are directing patients to these online pharmacies to reduce costs, incentivizing the purchase of unsafe drugs. Records obtained through FOIA requests show thousands of patients across multiple regions in Massachusetts are affected. Next steps include alerting regulatory agencies to intervene.

Counterfeit Drug Infographics for Interchange 2013

The Partnership For Safe Medicines

The document thanks sponsors for supporting the 2013 Interchange conference. It provides information about materials available to attendees, including a 69-page overview of counterfeit drug policy in the conference packet and educational materials that can be co-branded or used to educate communities. A USB pen is also described that contains graphics, research, and consumer education materials from the Partnership for Safe Medicines.

Americans patients exposed to counterfeit and black market medication

The Partnership For Safe Medicines

Fighting black market and counterfeit drugs in America endangers patients. Any break in the regulated, closed supply chain - whether by patients buying drugs online, or medical professionals purchasing from unlicensed distributors - puts lives at risk. Counterfeit or improperly handled treatments for conditions like HIV/AIDS, osteoporosis, kidney disease, and diabetes can be ineffective or even life-threatening when patients' health depends on properly manufactured and stored medicine. Protecting the supply chain is crucial to patient safety.

Viewers also liked (20)